Open for submissionsPeer reviewed, fully open access, and a low article processing charge.Submit manuscript

Research ArticleOpen AccessGoogle Scholar indexed

Theoretical Determination of Influence of the Metallic State of Oxidation toward Cytotoxic Activity: Case of Ruthenium Complexes

,
,
,
,
,
,
,
  1. 1 Laboratoire de Thermodynamique et Physico-Chimie du Milieu, Université Nangui Abrogoua, Abidjan, C&#244te d’Ivoire
Computational Chemistry·Volume 09, Issue 2·Pages 97–119·Published 29 April 2021·DOI10.4236/cc.2021.92006
Download PDF

Abstract

Ruthenium complexes present two states of oxidation that are Ru(II) and Ru(III). Both are assumed to present cytotoxic activity at ground state. On the purpose of highlighting their differences, DFT, TD-DFT and NBO have been performed at both Wb97xd/Lanl2dz and B3lyp/Lanl2dz levels. NBO program shows that both groups of ruthenium complexes present almost the same charge of Ru atom. Moreover, they display nearly the same structure of valence orbitals of the ruthenium. However, when it comes to compare their frontier orbitals HOMO and LUMO, we notice that the chloride atom has a great influence on their energy. The lack of Chloride atoms reduces the energy of frontier orbitals regardless of the functional. And the more the number of chloride atoms, the higher the energy. Also, RuCl3Terpy and α-RuCl2(Azpy)2 have been discovered to display the best energy suitable for reaction as cytotoxic agents. Yet, both are from groups different. Thus, at ground state, there is practically no difference between both groups. However, regarding TDDFT prediction with the determination of vertical electronic affinity VEA and vertical ionization potential VIP both at ground state S and at exciting T1 state, we notice that Ru(II) complexes are not active either in the presence or absence of 3O2 molecule. Here, only Ru(III) complexes are able to react on Guanine through their radical cations or by generating the superoxide radical anion . Therefore, the Ru(III) complexes are assumed to be active both at a fundamental state and under the effect of light for photodynamic therapy. We come to conclude that Ru(II) complexes are not active by excitation as their valence electrons are paired thereby making these complexes more stable. Besides, , a Ru(II) molecule that is not active at ground state owing certainly to its C3 symmetry or Azpy ligand presents all the same a difficult activity on generating . For the coming paper, we intend to check whether Ru(II) complex can be active under the effect of light if it is in a triplet charge state.

KeywordsNBOTD-DFTRu(II)Ru(III)Photo-Dynamic Therapy (PDT)
  1. Clarke, M.J., Zhu, F. and Frasca, D.R. (1999) Non-Platinum Chemotherapeutic Metallopharmaceuticals. Chemical Reviews, 99, 2511-2534. https://doi.org/10.1021/cr9804238
  2. Chen, H.M. Parkinson, J.A., Parson, S., Coxall, R.A., Grould, R.O. and Sadler, P.J. (2002) Organometallic Ruthenium(II) Diamine Anticancer Complexes: Arene- Nucleobase Stacking and Stereospecific Hydrogen-Bonding in Guanine Adducts. Journal of the American Chemical Society, 124, 3064-3082. https://doi.org/10.1021/ja017482e
  3. Urruticoechea, A., Alemany, R., Balart, J., Villanueva, A., Viñals, F. and Capellá, G. (2010) Recent Advances in Cancer Therapy: An Overview. Current Pharmaceutical Design, 16, 3-10. https://doi.org/10.2174/138161210789941847
  4. Pieter, P. and Lippard, S.J. (1997) Cisplatin and Related Drugs. Encyclopedia of Cancer, 1, 525-543.
  5. Zhang, C.X. and Lippard, S.J. (2003) New Metal Complexes as Potential Therapeutics, Current Opinion in Chemical Biology, 7, 481-489. https://doi.org/10.1016/S1367-5931(03)00081-4
  6. Wong, E. and Giandomenico, C.M. (1999) Current Status of Platinum-Based Antitumor Drugs. Chemical Reviews, 99, 2451-2466. https://doi.org/10.1021/cr980420v
  7. Lebwohl, D. and Canetta, R. (1998) Clinical Development of Platinum Complexes in Cancer Therapy: An Historical Perspective and an Update. European Journal of Cancer, 34, 1522-1534. https://doi.org/10.1016/S0959-8049(98)00224-X
  8. Wang, D. and Lippard, S.J. (2005) Cellular Processing of Platinum Anticancer Drugs. Nature Review Drug Discovery, 4, 307-320. https://doi.org/10.1038/nrd1691
  9. Galanski, M., Jakupec, M.A. and Keppler, B.K. (2005) Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Current Medicinal Chemistry, 12, 2075-2094. https://doi.org/10.2174/0929867054637626
  10. Garazd, Y., Garazd, M. and Lesyk, R. (2017) Synthesis and Evaluation of Anticancer Activity of 6-Pyrazolinylcoumarin Derivatives. Saudi Pharmaceutical Journal, 25, 214-223. https://doi.org/10.1016/j.jsps.2016.05.005
  11. Morsy, S.A., Farahat, A.A., Nasr, M.N.A. and Tantawy, A.S. (2017) Synthesis, Molecular Modeling and Anticancer Activity of New Coumarin Containing Compounds. Saudi Pharmaceutical Journal, 25, 873-883. https://doi.org/10.1016/j.jsps.2017.02.003
  12. Jamieson, E. and Lippard, S. (1999) Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chemical Reviews, 99, 2467-2498. https://doi.org/10.1021/cr980421n
  13. Antonarakis, E.S. and Emadi, A. (2010) Ruthenium-Based Chemotherapeutics: Are They Ready for Prime Time? Cancer Chemotherapy and Pharmacology, 66, 1-9. https://doi.org/10.1021/cr9804238
  14. Clarke, M.J., Zhu, F. and Frasca, D.R. (1999) Non-Platinum Chemotherapeutic Metallopharmaceuticals. Chemical Reviews, 99, 2511-2534.
  15. Chen, J.C., Li, J.L., Qian, L. and Zheng, K.C. (2005) Electronic Structures and SARs of the Isomeric Complexes α-, β-, γ-[Ru(mazpy)2Cl2] with Different Antitumor Activities. Journal of Molecular Structure: THEOCHEM, 728, 93-101. https://doi.org/10.1016/j.theochem.2005.05.005
  16. Notaro, A. and Gasser, G. (2017) Monomeric and Dimeric Coordinatively Saturated and Substitutionally Inert Ru(II) Polypyridyl Complexes as Anticancer Drug Candidates. Chemical Society Reviews, 46, 7317-7337. https://doi.org/10.1039/C7CS00356K
  17. Zhu, B.-Z., Chao, X.-J., Huang, C.-H. and Li, Y. (2016) Delivering the Cell-Impermeable DNA “Light-Switching” Ru(ii) Complexes Preferentially into Live-Cell Nucleus via an Unprecedented Ion-Pairing Method. Chemical Science, 7, 4016-4023. https://doi.org/10.1039/C5SC03796D
  18. Jenkins, Y., Friedman, A.E., Turro, N.J. and Barton, J.K. (1992) Characterization of Dipyridophenazine Complexes of Ruthenium(II): The Light Switch Effect as a Function of Nucleic Acid Sequence and Conformation. Biochemistry, 31, 10809-10816. https://doi.org/10.1021/bi00159a023
  19. Liu, J.-G., Ye, B.-H., Li, H., Zhen, Q.-X., Ji, L.-N. and Fu, Y.-H. (1999) Polypyridyl Ruthenium(II) Complexes Containing Intramolecular Hydrogen-Bond Ligand: Syntheses, Characterization, and DNA-Binding Properties. Journal of Inorganic Biochemistry, 76, 265-271. https://doi.org/10.1016/S0162-0134(99)00154-3
  20. Bamba, K., Leger, J.-M., Garnier, E., Bachmann, C., Servat, K. and Kokoh, K.B. (2005) Selective Electro-Oxidation of D-Glucose by RuCl2(azpy)2 Complexes as Electrochemical Mediators. Electrochimica Acta, 50, 3341-3346. https://doi.org/10.1016/j.electacta.2004.12.007
  21. De Sousa, K., Chagas, M., dos Santos, J., Galvão, A., de Moraes, F., Ribeiro, A., Fortaleza, D., da Encarnação Amorim, K. and dos Santos, W. (2018) Theoretical and Comparative Study of the Complex [RuCl3(H2O)2(Gly)] by Density Functional Theory. Open Journal of Inorganic Chemistry, 8, 43-53. https://doi.org/10.4236/ojic.2018.81004
  22. Vlan Vliet, P.M., Toekimin, S.M.S., Haasnoot, J.G., Reedijk, J., Novakova, O. and Brabec, V. (1995) mer-[Ru(terpy)Cl3] (terpy = 2,2':6',2"-terpyridine) Shows Biological Activity, Forms Interstrand Cross-Links in DNA and Binds Two Guanine Derivatives in a Trans Configuration. Inorganica Chimica Acta, 231, 57-64. https://doi.org/10.1016/0020-1693(94)04320-U
  23. Sava, G., Bergamo, A., Zorzet, S., Gava, B., Casarsa, C., Cocchietto, M., Furlani, A., Scarcia, V., Serli, B., Iengo, E., Alessio, E. and Mestroni, G. (2002) Influence of Chemical Stability on the Activity of the Antimetastasis Ruthenium Compound NAMI-A. European Journal of Cancer, 38, 427-435. https://doi.org/10.1016/S0959-8049(01)00389-6
  24. Chen, T., Liu, Y., Zheng, W.J., Liu, J. and Wong, Y.S. (2010) Ruthenium Polypyridyl Complexes that Induce Mitochondria-Mediated Apoptosis in Cancer Cells. Inorganic Chemistry, 49, 6366-6368. https://doi.org/10.1021/ic100277w
  25. Tan, C., Lai, S., Wu, S., Hu, S., Zhou, L., Chen, Y., Wang, M., Zhu, Y., Lian, W., Peng, W., Ji, L. and Xu, A. (2010) Nuclear Permeable Ruthenium(II) β-Carboline Complexes Induce Autophagy To Antagonize Mitochondrial-Mediated Apoptosis. Journal of Medicinal Chemistry, 53, 7613-7624. https://doi.org/10.1021/jm1009296
  26. Chagas, M.A.S., Galvão, A.D., de Moraes, F.T., Ribeiro, A.T.B.N., de Siqueira, A.B., de Assis Salama, I.C.C., Arrais-Silva, W.W., de Sousa, K.M.D., de Sousa Pereira, C.C. and dos Santos, W.B. (2017) Synthesis, Characterization and Analysis of Leishmanicide Ability of the Compound [Ru(Cl)3(H2O)2(gly)]. Open Journal of Inorganic Chemistry, 7, 89-101. https://doi.org/10.4236/ojic.2017.74006
  27. N’guessan, K.N., Guy-Richard Koné, M., Bamba, K., Wawohinlin Patrice, O. and Ziao, N. (2017) Quantitative Structure Anti-Cancer Activity Relationship (QSAR) of a Series of Ruthenium Complex Azopyridine by the Density Functional Theory (DFT) Method. Computational Molecular Bioscience, 7, 19-31. https://doi.org/10.4236/cmb.2017.72002
  28. Velders, A.H., Van der Schilden, K., Hoste, A.C.G., Reedijk, J., Kooijman, H. and Speck, A.L. (2004) Dichlorobis(2-phenylazopyridine)ruthenium(II) Complexes: Characterization, Spectroscopic and Structural Properties of Four Isomers. Dalton transactions, 3, 448-455. https://doi.org/10.1039/B313182C
  29. Hotze, A.C.G., Velders, A.H., Ugozzoli, F., Biagini-Cingi, M., Manotti-Lanfredi, A.M., Haasnoot, J.G. and Reedijk, J. (2000) Synthesis, Characterization, and Crystal Structure of α-[Ru(azpy)2(NO3)2] (azpy = 2-(Phenylazo)pyridine) and the Products of Its Reactions with Guanine Derivatives. Inorganic Chemistry, 39, 3838-3844. https://doi.org/10.1021/ic000066v
  30. Bamba, K., Ouattara, W.P., N’Guessan, K.N. and Ziao, N. (2016) SARs Investigation of α-, β-, γ-, δ-, ε -RuCl2(Azpy)2 Complexes as Antitumor Drugs. Computational Chemistry, 4, 1-10. https://doi.org/10.4236/cc.2016.41001
  31. Novakova, O., Kasparkova, J., Vrana, O., Van Vliet, P.M., Reedijk, J. and Brabec, V. (1995) Correlation between Cytotoxicity and DNA Binding of Polypyridyl Ruthenium Complexes. Biochemistry, 34, 12369-12378. https://doi.org/10.1021/bi00038a034
  32. Sava, G., Capozzi, I., Clerici, K., Gagliardi, G., Alessio, E. and Mestroni, G. (1998) Pharmacological Control of Lung Metastases of Solid Tumours by a Novel Ruthenium Complex. Clinical & Experimental Metastasis, 16, 371-379. https://doi.org/10.1023/A:1006521715400
  33. Lentz, F., Drescher, A., Lindauer, A., Henke, M., Hilger, R.A., Hartinger, C.G., Scheulen, M.E., Dittrich, C., Keppler, B.K. and Jaehde, U. (2009) Pharmacokinetics of a Novel Anticancer Ruthenium Complex (KP1019, FFC14A) in a Phase I Dose-Escalation Study. Anti-Cancer Drugs, 20, 97-103. https://doi.org/10.1097/CAD.0b013e328322fbc5
  34. Trondl, R., Heffeter, P., Kowol, C.R., Jakupec, M.A., Berger, W. and Keppler, B.K. (2014) NKP-1339, the First Ruthenium-Based Anticancer Drug on the Edge to Clinical Application. Chemical Science, 5, 2925-2932. https://doi.org/10.1039/C3SC53243G
  35. Hartinger, C.G., Zorbas-Seifried, S., Jakupec, M.A., Kynast, B., Zorbas, H. and Keppler, B.K. (2006) From Bench to Bedside—Preclinical and Early Clinical Development of the Anticancer Agent Indazolium Trans-[tetrachlorobis(1H-indazole) ruthenate(III)] (KP1019 or FFC14A). Journal of Inorganic Biochemistry, 100, 891-904. https://doi.org/10.1016/j.jinorgbio.2006.02.013
  36. Hotze, A.C.G., van der Geer, E.P.L., Kooijman, H., Spek, A.L., Haasnoot, J.G. and Reedijk, J. (2005) Characterization by NMR Spectroscopy, X-Ray Analysis an Cytotoxic Activity of Ruthenium (II) Compound Ru(L3) (PF6)2, (L) 2-Phenylazopyridine or o-Tolylazopyridine and Ru(L’2L’’) (PF6)2 (L’, L’’=2-Phenylazopyrine or 2,2’bipyridine). European Journal of Inorganic Chemistry, 2005, 2648-2657. https://doi.org/10.1002/ejic.200500110
  37. Das, C., Saha, A., Hung, C.-H., Lee, G.-H., Peng, S.-M. and Goswami, S. (2003) Ruthenium Complexes of 2-[(4-(Arylamino)phenyl)azo]pyridine Formed via Regioselective Phenyl Ring Amination of Coordinated 2-(Phenylazo)pyridine:Isolation of Products, X-ray Structure, and Redox and Optical Properties. Inorganic Chemistry, 42, 198-204. https://doi.org/10.1021/ic0203724
  38. Liu, J., Zou, X.-H., Zhang, Q.-L., Mei, W.-J., Liu, J.-Z. and Ji, L.-N. (2000) Synthesis, Characterization and Antitumor Activity of a Series of Polypyridyl Complexes. Metal-Based Drugs, 7, Article ID: 427618. https://doi.org/10.1155/MBD.2000.343
  39. Dwyer, F.P., Gyarfas, E.C., Rogers, W.P. and Koch, J.H. (1952) Biological Activity of Complex Ions. Nature, 170, 190-191. https://doi.org/10.1038/170190a0
  40. Allardyce, C.S. and Dyson, P.J. (2001) Ruthenium in Medicine: Current Clinical Uses and Future Prospects. Platinum Metals Review, 45, 62-69.
  41. Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G.A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H.P., Izmaylov, A.F., Bloino, J., Zheng, G., Sonnenberg, J.L., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Montgomery Jr., J.A., Peralta, J.E., Ogliaro, F., Bearpark, M.J., Heyd, J., Brothers, E.N., Kudin, K.N., Staroverov, V.N., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A.P., Burant, J.C., Iyengar, S.S., Tomasi, J., Cossi, M., Rega, N., Millam, N.J., Klene, M., Knox, J.E., Cross, J.B., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R.E., Yazyev, O., Austin, A.J., Cammi, R., Pomelli, C., Ochterski, J.W., Martin, R.L., Morokuma, K., Zakrzewski, V.G., Voth, G.A., Salvador, P., Dannenberg, J.J., Dapprich, S., Daniels, A.D., Farkas, Ö., Foresman, J.B., Ortiz, J.V., Cioslowski, J. and Fox, D.J. (2009) Gaussian 09. Gaussian, Inc. Print, Wallingford.
  42. Shriver, D.F. and Atkins, P.W. (1999) Inorganic Chemistry. 3rd Edition, De Boeck University, Paris, p. 229.
  43. Nobel, N.K., Bamba, K., Patrice, O.W. and Ziao, N. (2017) NBO Population Analysis and Electronic Calculation of Four Azopyridine Complexes by DFT Method. Computational Chemistry, 5, 51-64. https://doi.org/10.4236/cc.2017.51005
  44. Kurita, N. and Kobayashi, K. (2000) Density Functional MO Calculation for Stacked DNA Base-Pairs with Backbones. Computers & Chemistry, 24, 351-357. https://doi.org/10.1016/S0097-8485(99)00071-6
  45. Velders, A.H., Kooijman, H., Spek, A.L., Haasnoot, J.G., De Vos, D. and Reedijk, J. (2000) Strong Differences in the in Vitro Cytotoxicity of Three Isomeric Dichlorobis(2-phenylazopyridine)ruthenium(II) Complexes. Inorganic Chemistry, 39, 2966- 2967. https://doi.org/10.1021/ic000167t
  46. Zhao, X., Zheng, Z., Feng, S., Shi, Z. and Chen, D. (2009) A TD-DFT Study on the Photo-Physicochemical Properties of Chrysophanol from Rheum. International Journal of Molecular Sciences, 10, 3186-3193. https://doi.org/10.3390/ijms10073186
  47. Liu, J., Zhao, Y.W., Zhao, J.Q., Xia, A.D., Jiang, L.J., Wu, S., Ma, L., Dong, Y.Q. and Gu, Y.H. (2002) Two-Photon Excitation Studies of Hypocrellins for Photodynamic Therapy. Journal of Photochemistry and Photobiology B: Biology, 68, 156-164. https://doi.org/10.1016/S1011-1344(02)00379-2
  48. Wu, W., Shao, X., Zhao, J. and Wu, M. (2017) Controllable Photodynamic Therapy Implemented by Regulating Singlet Oxygen Efficiency. Advanced Science, 4, 1700113. https://doi.org/10.1002/advs.201700113
  49. Ouattara, W., Bamba, K., Thomas, A., Diarrassouba, F., Ouattara, L., Ouattara, M., N'guessan, K., Kone, M., Kodjo, C. and Ziao, N. (2021) Theoretical Studies of Photodynamic Therapy Properties of Azopyridineδ-OsCl2(Azpy)2 Complex as a Photosensitizer by a TDDFT Method. Computational Chemistry, 9, 64-84. https://doi.org/10.4236/cc.2021.91004
  50. Rodica-Mariana, I. (2007) Photodynamic Therapy (PDT): A Photochemical Concept with Medical Applications. Revue Roumaine de Chimie, 52, 1093-1102.
  51. de Oliveira, K.T., de Souza, J.M., Gobo, N.R.S., de Assis, F.F. and Brocksom, T.J. (2015) Basic Concepts and Applications of Porphyrins, Chlorins and Phthalocyanines as Photosensitizers in Photonic Therapies. Revista Virtual de Quimica, 7, 310-335. https://doi.org/10.5935/1984-6835.20150016
  52. Musa, K.A.K., Matxain, J.M. and Eriksson, L.A. (2007) Mechanism of Photoinduced Decomposition of Ketoprofen. Journal of Medicinal Chemistry, 50, 1735-1743. https://doi.org/10.1021/jm060697k
  53. Sousa, F.F.R., Quartarolo, A.D., Sicilia, E. and Russo, N. (2012) A Time-Dependent Density Functional Study of a Non-Aromatic [1.1.1.1.1]-Pentaphyrin and Its Lutetium Complex. The Journal of Physical Chemistry B, 116, 10816-10823. https://doi.org/10.1021/jp3068359
  54. Shen, L., Ji, H.F. and Zhang, H.Y. (2006) A TD-DFT Study on Photo-Physicochemical Properties of Hypocrellin A and Its Implications for Elucidating the Photosensitizing Mechanisms of the Pigment. Journal of Photochemistry and Photobiology A: Chemistry, 180, 65-68. https://doi.org/10.1016/j.jphotochem.2005.09.019